Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,012 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adverse Events Clear all
Completed Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

NCT04927975
View directory record Official record
Conditions
Non-Segmental Vitiligo
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Irvine, California • Redwood City, California • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 31, 2026, 6:44 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988
View directory record Official record
Conditions
Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers
Interventions
Mirvetuximab Soravtansine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Sarasota, Florida • Edgewood, Kentucky • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Phase 2 Interventional Results available

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

NCT01009918
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 31, 2026, 6:44 AM EDT
Completed No phase listed Observational

Peri-Intubation Adverse Airway Events in Critically Ill Patients With Morbid and Super Obesity

NCT07297420
View directory record Official record
Conditions
Obesity, Airway Complication of Anesthesia, Intubation; Difficult or Failed
Interventions
endotracheal intubation
Procedure
Lead sponsor
Zeliha Alicikus
Government
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Adverse Events of MRI With Abandoned Leads

NCT04478773
View directory record Official record
Conditions
Pacemaker Electrode Lead Fracture, ICD
Interventions
MRI
Procedure
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 31, 2026, 6:44 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Terminated Phase 2Phase 3 Interventional

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT04857359
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Fresno, California • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 31, 2026, 6:44 AM EDT
Withdrawn No phase listed Observational

T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events

NCT01796743
View directory record Official record
Conditions
Myocardial Infarction, Acute
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 31, 2026, 6:44 AM EDT
Completed No phase listed Observational

A Study to Assess the Hypersensitivity to TAK-880 Compared to Gammagard S/D in Blood of Children, Teenagers and Adults

NCT05269082
View directory record Official record
Conditions
Drug Hypersensitivity
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Not applicable Interventional

Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy

NCT03964896
View directory record Official record
Conditions
Breast Carcinoma, Head and Neck Carcinoma, Sarcoma
Interventions
Survey, Survey Administration, Telephone-Based Intervention
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 31, 2026, 6:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of Infection Rates Between Two Surgical Sites

NCT01263262
View directory record Official record
Conditions
Corneal Toxicity, Ototoxicity, Surgical Site Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 31, 2026, 6:44 AM EDT
Withdrawn Not applicable Interventional

Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant

NCT02812082
View directory record Official record
Conditions
Allo-SCT Patients, Adult Allo-SCT Survivor
Interventions
web-based patient education, questionnaire
Other · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 31, 2026, 6:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Preoperative Exercise Testing and Perioperative Outcomes

NCT07519733
View directory record Official record
Conditions
Postoperative Complications (Cardiopulmonary)
Interventions
Recruited participants receive preoperative rapid submaximal cardiopulmonary exercise testing within the current risk assessment framework of the pre-surgical evaluation clinic
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
45 Years and older
Enrollment
992 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Phase 2 Interventional

Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00003089
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Interventions
amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Phase 2 Interventional Results available

A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects

NCT00187226
View directory record Official record
Conditions
Central Nervous System Tumors, Brain Tumors
Interventions
Radiation Therapy
Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Months to 25 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Not applicable Interventional

Effective Communication for Preventing and Responding to Oncology Adverse Events

NCT01871948
View directory record Official record
Conditions
Cancer
Interventions
"We Want to Know" campaign, Patient survey at 2 time points
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
21 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 31, 2026, 6:44 AM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Phase 2 Interventional Results available

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

NCT02819479
View directory record Official record
Conditions
Radiation Necrosis
Interventions
25% Mannitol, Low-dose Intra-arterial Bevacizumab
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 31, 2026, 6:44 AM EDT
Recruiting No phase listed Observational

Post-market Safety Study of LUMISIGHT

NCT07572162
View directory record Official record
Conditions
Hypersensitivity Reactions
Interventions
Not listed
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Mobile, Alabama • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Phase 3 Interventional

Robotic Assisted Laparoscopic Prostatectomy With or Without Pelvic Drain Placement in Reducing Adverse Events After Surgery in Patients With Prostate Cancer

NCT01613651
View directory record Official record
Conditions
Perioperative/Postoperative Complications, Prostate Cancer
Interventions
robot-assisted laparoscopic surgery, questionnaire administration, intraoperative complication management/prevention
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 31, 2026, 6:44 AM EDT
Active, not recruiting Phase 2 Interventional

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

NCT05722288
View directory record Official record
Conditions
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IB Cervical Cancer FIGO 2018, Stage IB2 Cervical Cancer FIGO 2018, Stage II Prostate Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Prostate Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Short-Term Fasting
Procedure · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724
View directory record Official record
Conditions
Dry Eye Syndrome, Systemic Lupus Erythematosus
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 31, 2026, 6:44 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 31, 2026, 6:44 AM EDT
Completed No phase listed Observational

Detection of Chemotherapy Induced Cardiotoxicity

NCT00636844
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 31, 2026, 6:44 AM EDT